Post-approval TAVI registry shows high rates of device success at one year
One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries
21 May 2013, Paris, France: One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, with high rates of device success for all access approaches, valve sizes and delivery systems.
The SOURCE XT Post-Approval Study followed up 2688 consecutively enrolled patients (mean age 81.5 years) undergoing TAVI with the Sapien XT heart valve at 93 centres in 17 countries between July 2010 and October 2011. Access was transfemoral, transapical, transaortic or transsubclavian. Events were adjudicated by an independent clinical event committee.
“Results for one-year outcomes showed a large treatment effect in terms of symptom relief and improved quality of life,” reported Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland. Patients showed sustained improvement in effective orifice area, with low rates of moderate or severe aortic regurgitation.
“One-year mortality and stroke rates were low in this elderly population,” Windecker said. The all-cause mortality rate was 19.5% and the stroke rate 6.3% overall. But he noted that one-year survival associated with all-cause mortality was higher in women (90.6%) than in men (87.6%; p=0.0075) and survival associated with cardiac mortality was also higher.
Windecker concluded, “SOURCE XT showed high rates of device success for all access approaches, valve sizes and delivery systems.”
Notes to Editors
For more information on this press release, interviews and photographs, please contact Isabelle Uzielli, email: iuzielli@europcr.com
What is EuroPCR?
EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) and the world-leading course in interventional medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore, London, Dubai and Cape Town.
For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR & PCR, please contact: Anne-Sophie Lartigau at
aslartigau@europa-organisation.com
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.